Pharma's future

Eduardo Gotuzzo; Melissa Brosset; Camila Masias; Natalia Freundt; Maria Jose Inurritegui

Pharma's future

Eduardo Gotuzzo
, Melissa Brosset
, Camila Masias
, Natalia Freundt
, Maria Jose Inurritegui

Gotuzzo Asociados

Research output: Contribution to journal › Short survey › peer-review

Abstract

Latin America is an emerging region with great potential due to its short regulatory timelines, experienced sites and lower costs. As an important destination for clinical research, the region is constantly being audited by both sponsors and the FDA alike, and continues to produce excellent results.

Original language	English
Pages (from-to)	78-81
Number of pages	4
Journal	European Pharmaceutical Contractor
Issue number	SUMMER
State	Published - Jun 2011
Externally published	Yes

Cite this

@article{3a6b9879a5f64571be62ab51b0fdc3c4,

title = "Pharma's future",

abstract = "Latin America is an emerging region with great potential due to its short regulatory timelines, experienced sites and lower costs. As an important destination for clinical research, the region is constantly being audited by both sponsors and the FDA alike, and continues to produce excellent results.",

author = "Eduardo Gotuzzo and Melissa Brosset and Camila Masias and Natalia Freundt and Inurritegui, \{Maria Jose\}",

year = "2011",

month = jun,

language = "Ingl{\'e}s",

pages = "78--81",

journal = "European Pharmaceutical Contractor",

issn = "1364-369X",

number = "SUMMER",

}

TY - JOUR

T1 - Pharma's future

AU - Gotuzzo, Eduardo

AU - Brosset, Melissa

AU - Masias, Camila

AU - Freundt, Natalia

AU - Inurritegui, Maria Jose

PY - 2011/6

Y1 - 2011/6

N2 - Latin America is an emerging region with great potential due to its short regulatory timelines, experienced sites and lower costs. As an important destination for clinical research, the region is constantly being audited by both sponsors and the FDA alike, and continues to produce excellent results.

AB - Latin America is an emerging region with great potential due to its short regulatory timelines, experienced sites and lower costs. As an important destination for clinical research, the region is constantly being audited by both sponsors and the FDA alike, and continues to produce excellent results.

UR - https://www.scopus.com/pages/publications/79958185113

M3 - Estudio breve

AN - SCOPUS:79958185113

SN - 1364-369X

SP - 78

EP - 81

JO - European Pharmaceutical Contractor

JF - European Pharmaceutical Contractor

IS - SUMMER

ER -

Pharma's future

Abstract

Other files and links

Fingerprint

Cite this